Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  The Lancet

• Publication date

  2008-07-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(08)61011-9PMID 18620932
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

  2009cited by this paper
• Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma

  2008cited by this paper
• Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

  2008cited by this paper
• Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma

  2008cited by this paper
• Prognostic Significance of Autoimmunity during Treatment of Melanoma with interferon

  2007cited by this paper
• Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials

  2007cited by this paper
• Prognostic significance of autoimmunity during treatment of melanoma with interferon.

  2006cited by this paper
• Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.

  2005cited by this paper
• Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?

  2004cited by this paper
• A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma

  2004cited by this paper
• Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

  2002cited by this paper
• Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.

  2002cited by this paper
• Cancer : Principles and Practice of Oncology

  1982cited by this paper

• Which Approach Is More Effective in Maternal and Child Health; Primary Health Care or Specialization?

  2020cites this paper
• Interferon alpha-induced reduction in the values of myeloid-derived suppressor cells in melanoma patients.

  2015cites this paper
• Adjuvant therapy for melanoma: a surgical perspective.

  2011cites this paper
• The Role of Electrochemotherapy in the Treatment of Malignant Melanoma

  2011cites this paper
• Opportunistic autoimmune disorders

  2010cites this paper
• Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma.

  2010cites this paper
• Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

  2010cites this paper
• Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

  2009cites this paper
• Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies

  2009cites this paper
• Pegylated Interferons in the Adjuvant Treatment of Melanoma

  2009cites this paper
• Update zur Epidemiologie, Diagnostik und Therapie des malignen Melanoms

  2009cites this paper
• Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it?

  2009cites this paper
• Sentinel node biopsy needs for a suitable therapeutic management of the cutaneous melanoma

  2009cites this paper
• Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma

  2009cites this paper